Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Stock Symbol: REGN
Stock Exchange: NASDAQ
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Learn more about how our team produces the highest-quality treatments for patients at https://www.regeneron.com/.
1384 articles about Regeneron Pharmaceuticals, Inc.
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
Regeneron Pharmaceuticals, Inc. announced new and updated data for odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary endpoint analysis from the pivotal trial (LINKER-MM1) investigating linvoseltamab demonstrated high rates of deep and durable responses in patients with relapsed/refractory (R/R) multiple myeloma (MM).
Regeneron Pharmaceuticals, Inc. announced the presentation of new and updated data on multiple combination therapies from its oncology pipeline at the European Society for Medical Oncology Immuno-Oncology Congress 2023 from December 6 to 8 in Geneva, Switzerland.
While almost half of multiple myeloma patients on linvoseltamab achieved a complete response or better, all experienced adverse events and 14 patients died due to treatment-emergent AEs.
EyePoint Pharmaceuticals’ treatment for wet age-related macular degeneration showed comparable results to Regeneron’s Eylea with a less frequent dosing regimen.
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to provide an update on the company's hematology portfolio on Thursday, December 14, 2023 at 8:30 AM ET.
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
The second Dupixent® investigational Phase 3 chronic obstructive pulmonary disease trial has shown that Dupixent significantly reduced exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the second Dupixent® investigational Phase 3 chronic obstructive pulmonary disease trial showed that Dupixent significantly reduced exacerbations, confirming positive results from the landmark Phase 3 BOREAS trial.
Regeneron Pharmaceuticals, Inc. will webcast management participation.
While Regeneron Pharmaceuticals reported better-than-expected third-quarter results, sales of the company’s lead drug Eylea declined amid increased competition.
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its hematology pipeline will be shared in 19 abstracts at the American Society of Hematology (ASH) Annual Meeting from December 9 to 12 in San Diego, CA.
Regeneron Pharmaceuticals, Inc. announced financial results for the third quarter of 2023 and provided a business update.
EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema
Regeneron Pharmaceuticals, Inc. announced long-term outcomes and new analyses of pivotal clinical data for EYLEA® HD Injection 8 mg will be presented at the American Academy of Ophthalmology annual meeting in San Francisco from November 3 to 6.
Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced preliminary, positive safety and efficacy results from the first patient (<2 years of age) dosed in the Phase 1/2 CHORD trial investigating otoferlin gene therapy (DB-OTO) in children with profound genetic hearing loss due to mutations of the otoferlin gene.
Regeneron Pharmaceuticals, Inc. will webcast management participation as follows.
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
Positive results from a Phase 3 trial demonstrated the efficacy and safety profile of Dupixent® for up to one year in children aged 1 to 11 years with eosinophilic esophagitis was consistent.
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
Regeneron Pharmaceuticals, Inc. and Sanofi announced that positive results from a Phase 3 trial evaluating the investigational use of Dupixent® showed consistent efficacy and safety for up to one year in children aged 1 to 11 years with eosinophilic esophagitis.
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
Regeneron Pharmaceuticals, Inc. announced the first presentation of key secondary endpoints for an investigational regimen of PD-1 inhibitor Libtayo® as a neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in chronic spontaneous urticaria (CSU).
Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN
Regeneron Pharmaceuticals, Inc. announced a five-year, $5 million strategic investment to bolster Nashville, Tennessee’s science, technology, engineering and mathematics ecosystem through high-quality, equitable engagement programs for students and science teachers.